Estrogen replacement therapy in women with a history of proliferative breast disease

Cancer

Volumn 85, Issue 6, 1999, Pages 1277-1283

  Dupont, William D ^a   Page, David L ^b   Parl, Fritz F ^b   Plummer Jr , W Dale ^a   Schuyler, Peggy A ^a   Kasami, Masako ^b   Jensen, Roy A ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Atypical hyperplasia; Breast neoplasms; Complex fibroadenoma; Estrogen replacement therapy; Proliferative breast disease

Indexed keywords

ESTROGEN;

ADULT; ARTICLE; BENIGN TUMOR; BREAST BIOPSY; BREAST CARCINOMA; CANCER RISK; DRUG EFFECT; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; BREAST DISEASES; BREAST NEOPLASMS; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; FIBROADENOMA; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; RISK FACTORS;

EID: 0033559624     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990315)85:6<1277::AID-CNCR9>3.0.CO;2-E     Document Type: Article

References (54)

1. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-71.
2. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
3. Adami HO, Persson I. Hormone replacement and breast cancer. A remaining controversy? JAMA 1995;274:178-9.
4. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
5. Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987;94:620-35.
6. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-9.
7. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988;159:312-7.
8. Criqui MH, Suarez L, Barrett-Connor E, McPhillips J, Wingard DL, Garland C. Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community. Am J Epidemiol 1988;128:606-14.
9. Grodstein F, Stampfer MJ, Mansen JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
10. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
11. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.
12. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;276:1389-96.
13. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995:122:9-16.
14. Lindsay R, Cosman F. Estrogen in prevention and treatment of osteoporosis. Ann N Y Acad Sci 1990;592:326-33.
15. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164-7.
16. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167-70.
17. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
18. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-990.
19. Brinton LA, Hoover R, Fraumeni JF, Jr. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986;54:825-32.
20. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293-7.
21. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark, Int J Cancer 1988;42:832-8.
22. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
23. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312:146-51.
24. Palli D, Rosselli del Turco M, Simoncini R, Bianchi S. Benign breast disease and breast cancer: a case-control study in a cohort in Italy, Int J Cancer 1991;47:703-6.
25. London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992;267:941-4.
26. Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71:1258-65.
27. Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD, Jr., Rados MS, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 1994;331:10-5.
28. Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997;6:297-301.
29. Ross RK, Paganini-Hill A, Gerkins VR, Mack TM, Pfeffer R, Arthur M, et al. A case-control study of menopausal estrogen therapy and breast cancer. JAMA 1980;243:1635-9.
30. Wingo PA, Layde PM, Lee NC, Rubin G, Ory HW. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA 1987;257:209-15.
31. Rohan TE, McMichael AJ. Non-contraceptive exogenous oestrogen therapy and breast cancer. Med J Aust 1988;148: 217-21.
32. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67-72.
33. Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, et al. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol 1991;134:1375-85.
34. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S. Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study. Am J Epidemiol 1991;134:1386-95.
35. Newcomb PA, Longnecker MP, Storer BE, Mittendorf R, Baron J, Clapp RW, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995;142:788-95.
36. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137-42.
37. Dupont WD, Page DL, Rogers LW, Parl FF. Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer 1989;63:948-57.
38. Dupont WD, Page DL. Letter to the editor (Author's reply). Cancer 1990;65:1261-62.
39. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55:2698-708.
40. Dupont WD, Page DL. Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. Am J Epidemiol 1987;125:769-79.
41. Dupont WD, Page DL. Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. Hum Pathol 1989;20:723-5.
42. Page DL, Anderson TJ, Rogers LW. Epithelial hyperplasia. In: Page DL, Anderson T. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone, 1987:120-56.
43. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 1992;23:1095-7.
44. Breslow NE, Day NE. Statistical methods in cancer research. Volume II. The design and analysis of cohort studies. Lyon, France: IARC Scientific Publications, 1987.
45. Stuart A, Ord JK. Kendall's advanced theory of statistics. Volume 2. Classical inference and relationship. London: Edward Arnold, 1991.
46. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:1-30.
47. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
48. Rosner B. Fundamentals of biostatistics. Belmont, CA: Wadsworth Publishing Company, 1995.
49. SAS Institute Inc. SAS/STAT user's guide. Version 6. 4th edition. Volume 1. Cary, NC: SAS Institute, Inc., 1989.
50. SAS Institute Inc. SAS/STAT user's guide. Version 6. 4th edition. Volume 2. Cary, NC: SAS Institute, Inc., 1989.
51. SAS Institute Inc. SAS technical report P-229. SAS/SAT software: changes and enhancements. Release 6.07. Cary, NC: SAS Institute, Inc., 1992.
52. Cambrell RD Jr., Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 1983;62:435-43.
53. Yang CP, Daling JR, Band PR, Gallagher RP, White E, Weiss NS. Noncontraceptive hormone use and risk of breast cancer. Cancer Causes Control 1992;3:475-9.
54. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994;5:491-500.